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Abstract
Background: Nonmedical prescription opioid use (NMPOU) is a serious public health problem in North America. At
a population-level, previous research has identified differences in the prevalence and correlates of NMPOU among
younger versus older age groups; however, less is known about age-related differences in NMPOU among people
who use illegal drugs.
Methods: Data were collected between 2013 and 2015 from two linked prospective cohort studies in Vancouver,
Canada: the At-Risk Youth Study (ARYS) and the Vancouver Injection Drug Users Study (VIDUS). Factors independently
associated with NMPOU among younger (ARYS) and older (VIDUS) participants were examined separately using
bivariate and multivariate generalized estimating equations.
Results: A total of 1162 participants were included. Among 405 eligible younger participants (Median age = 25;
Inter-Quartile Range [IQR]: 22–28), 40% (n = 160) reported engaging in NMPOU at baseline; among 757 older
participants (Median age = 48, IQR: 40–55), 35% (n = 262) reported engaging in NMPOU at baseline. In separate
multivariate analyses of younger and older participants, NMPOU was positively and independently associated with
heroin use (younger: Adjusted Odds Ratio [AOR] = 3.12, 95% Confidence Interval [CI]: 2.08–4.68; older: AOR = 2.79, 95%
CI: 2.08–3.74), drug dealing (younger: AOR = 2.22, 95% CI: 1.58–3.13; older: AOR = 1.87, 95% CI: 1.40–2.49), and difficulty
accessing services (younger: AOR = 1.47, 95% CI: 1.04–2.09; older: AOR = 1.74, 95% CI: 1.32–2.29). Among the youth
cohort only, NMPOU was associated with younger age (AOR = 1.12, 95% CI: 1.05–1.19), crack use (AOR = 1.56, 95% CI: 1.
06–2.30), and binge drug use (AOR = 1.41, 95% CI: 1.00–1.97); older participants who engaged in NMPOU were more
likely to report crystal methamphetamine use (AOR = 1.97, 95% CI: 1.46–2.66), non-fatal overdose (AOR = 1.76, 95% CI: 1.
20–2.60) and sex work (AOR = 1.49, 95% CI: 1.00–2.22).
Discussion: The prevalence of NMPOU is similar among younger and older people who use drugs, and independently
associated with markers of vulnerability among both age groups. Adults who engage in NMPOU are at risk for non-fatal
overdose, which highlights the need for youth and adult-specific strategies to address NMPOU that include better access
to health and social services, as well as a range of addiction treatment options for opioid use. Findings also underscore
the importance of improving pain treatment strategies tailored for PWUD.
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Background
Rates of medical and nonmedical prescription opioid use
(NMPOU) are rising across Canada and the United States
[1], along with shifts towards increases in the global con-
sumption of opioids [2]. Research consistently indicates
that adolescents and young adults are more likely to en-
gage in NMPOU than older youth and adults [3–11], and
evidence suggests that these differences in prescription
opioid (PO) use are associated with statistically significant
birth cohort effects; more recent birth cohorts have higher
lifetime and past-year prevalence of prescription opioid
-use disorder due to NMPOU [12]. Adolescents and
young adults in the United States are more likely to initi-
ate NMPOU than older age groups [3, 13–15], and a study
of the American general population found that the most
frequently reported age of NMPOU initiation was 16–18
years [16]. This effect has been attributed to the increased
availability of POs [4], and other research among
street-involved youth has found that the easy availability
of POs facilitates NMPOU [17]. In addition, those who
engage in NMPOU are more likely to be younger than
those engaging in other illegal drug use [18], and adoles-
cents and young adults are also more likely to share and
receive any class of prescription medications, including
POs, than older age groups [19]. For the purposes of this
study, “youth”, “young adult”, and “younger age groups”
are used to describe individuals in their late teens and up
to the late 20’s [20]. “Adult” and “older age groups”
include those over the age of majority but focuses on
those in their mid-life and older.
Youth-specific strategies to address substance use are
often prioritized due to the developmental harms associ-
ated with licit and illegal substances [21]; however, the
prevalence of NMPOU among adults up to age 64 is sig-
nificantly higher than among adults over the age of 65
[22], and the ubiquity of PO use has resulted in a signifi-
cant risk of engaging in NMPOU that increases with age
[12]. The increase in PO use among older individuals is
especially problematic given that age-related physiological
changes (e.g., drug absorption) increase the harms of PO
use among older adults, such as hyperalgesia [23].
Research has also identified a key difference related to
NMPOU among younger and older age groups, where
pain is a more frequent motivator for engaging in
NMPOU among adults [24] and youth are more likely to
engage in NMPOU for its euphoric effects [6].
Although younger and older age groups are both at risk
for engaging in NMPOU, the majority of research findings
related to NMPOU rely on population-level sampling and
national surveys that often exclude marginalized groups
who are unstably housed or have low incomes. Despite
previous research investigating NMPOU among people
who use illegal drugs (PWUD) in Canadian and American
settings [17, 25–34], there have been few if any studies
characterizing age-based differences associated with
NMPOU among PWUD. Given that this population
already experiences numerous risks and harms related to
substance use [35], this study investigates age-based differ-
ences associated with NMPOU among younger and older
PWUD in Vancouver.
Methods
Data from this study were drawn from two prospective
open cohort studies: the At-Risk Youth Study (ARYS) and
the Vancouver Injection Drug Users Study (VIDUS).
ARYS and VIDUS use a harmonized study questionnaire
and study participants can attend a study visit at either
study office regardless of their cohort enrollment. ARYS
and VIDUS have both been described in detail previously
[36, 37]. VIDUS is a cohort of HIV-negative adult PWUD
who injected illegal drugs at least once in the month prior
to enrolment. Participants in the VIDUS cohort are
recruited through self-referral and street outreach, which
has been ongoing since 1996. In brief, ARYS has been
operating since 2005 as a cohort study of street-involved
youth. To be eligible, participants must be aged 14–26
years at recruitment and also have used illegal drugs other
than cannabis in the past 30 days, provide written
informed consent, and be “street-involved”. In this cohort,
“street-involved” is defined as being absolutely, periodic-
ally, or temporarily homeless (e.g., having no fixed
address, sleeping on the street, couch surfing, or staying in
a shelter or hostel), and includes those who are not home-
less but have used services designated for street-youth
(e.g., youth-specific drop-in centres, social services, and
harm reduction services) in the last year. Youths’ street
involvement and eligibility to participate are assessed dur-
ing a semi-structured in-person interview with an ARYS
staff member.
At enrolment, and on a semi-annual basis, participants
in ARYS and VIDUS complete a questionnaire that is
administered by trained study staff. The questionnaire
includes questions related to demographic information
and drug use patterns. At each study visit, participants
are provided with a stipend ($30 CDN) for their time.
The ARYS and VIDUS studies have been approved by
the University of British Columbia/Providence Health
Care Research Ethics Board.
All ARYS and VIDUS participants who completed a
study visit between December 2013 and May 2015 were
eligible for the present analyses, as PO-related questions
were added to the study instrument during the summer of
2013. The dependent variable for these analyses was
engaging in NMPOU through any route of administration,
based on responses to the question: “In the last 6 months,
when you were using, which of the following non
-injection prescription opiates did you use when they were
not prescribed for you or that you took only for the
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experience or feeling they caused, and how often did you
use them?” and “In the last 6 months, have you injected
any of the following prescription opiates?” (yes vs. no). To
identify factors associated with engaging in NMPOU, we
considered a number of potential explanatory variables of
interest. The following socio-demographic variables of
interest were included: age (per year younger); sex; Cauca-
sian ancestry; and homelessness, defined as having no
fixed address, sleeping on the street, couch surfing, or
staying in a shelter or hostel in the last 6 months. The fol-
lowing variables related to drug use were also included:
any injection or non-injection heroin use; any injection or
non-injection crack cocaine use; any injection or
non-injection cocaine use; any injection or non-injection
crystal methamphetamine use; binge drug use, defined as
a period of using injection or non-injection drugs more
often than usual; and experiencing a non-fatal drug over-
dose due to injection or non-injection drug use, based on
responses to the question “In the last 6 months, have you
overdosed by accident (i.e., where you had a negative reac-
tion from using too much drugs)?”. Behavioural and
socio-structural risk factors hypothesized to be associated
with NMPOU included: regular employment, defined as
having a regular job, temporary work, or being self
-employed; drug dealing, defined as selling drugs as a
source of income; engaging in sex work, defined as ex-
changing sex for money, drugs, gifts, food, clothes, shelter
or favours; incarceration, defined as being in detention,
jail, or prison; and difficulty accessing services, based on
responses to the question “In the last 6 months, was there
a time you were in need of a service (e.g., housing, coun-
selling) but could not obtain it?”. All variables were binary
and referred to activities, behaviours, and experiences in
the previous 6 months unless otherwise indicated.
All analyses were conducted separately for ARYS and
VIDUS participants, using cohort enrollment as a proxy
marker for younger and older age groups, respectively. At
the time of enrollment, ARYS participants must be between
14 and 26 years old; however, as a prospective cohort study
with substantial resources devoted to maintaining follow-up,
the ARYS participant pool necessarily includes participants
who are older than 26. These participants and their data are
not excluded from the analyses given that this data provides
a rich source for tracking and understanding long-term risk
trajectories associated with street-involvement during a key
developmental phase. While this practice may limit the ap-
plicability of our results to street-involved adolescents, we
controlled for possible biases associated with these older
participants in the youth cohort by including the continuous
“per year younger” variable in the analyses to ensure that
age differences within the cohort were accounted for. For
consistency and to similarly control for a wide age range
within the cohort, we also included the “per year younger”
variable in the VIDUS analysis.
First, a descriptive analysis of the study sample was con-
ducted using Pearson’s chi-square test. Characteristics for
participants who reported nonmedical prescription opioid
use (NMPOU) were measured at their first visit (during
the study period: 2013–2015), which involved a report of
NMPOU; characteristics for all other participants were
measured from the first study visit during the study
period. Second, to model factors associated with engaging
in NMPOU over time and to analyse longitudinal corre-
lated within-subject data [38, 39], generalized estimating
equation (GEE) analyses were performed. These methods
provide standard errors adjusted by multiple observations
per person using an exchangeable working correlation
structure. The GEE estimating mechanism uses all avail-
able pairs method to encompass any missing data from
dropouts or other intermittent missing. All non-missing
pairs of data are used in the estimators of the working cor-
relation parameters [40].
As a first step, GEE bivariate analyses were conducted
to determine factors associated with engaging in
NMPOU. Variables significant in the bivariate analyses
at p < 0.10 were considered for a full multivariate model.
A backwards selection procedure was used to identify
the model with the best overall fit as indicated by the
lowest quasi-likelihood under the independence model
criterion (QIC) value [41]. The QIC value was selected
instead of the more recently developed Correlation
Information Criterion (CIC), as the CIC is used to select
the appropriate intracluster correlation structure, and is
not used for covariate selection; we required a mechan-
ism that could address both these needs simultaneously
[42]. All statistical analyses were performed using SAS
software version 9.4 (SAS, Cary, NC). All p-values were
two sided.
Results
A total of 405 ARYS and 757 VIDUS participants were
eligible for this study. For ARYS, 313 (77.3%) partici-
pants were enrolled before December 2013 and 92
(22.7%) participants were newly enrolled during the
study period. For the 313 participants, the median age at
the first study visit within the study period for the
current analysis was 26 (IQR: 23–28); and for the 92
participants, the median age at study enrollment was 21
(IQR: 20–23). For VIDUS, 697 (92.1%) participants were
enrolled before December 2013 and 60 (7.9%) partici-
pants were newly enrolled during the study period.
Among these 697 participants, the median age at the
first study visit within study period was 49 (IQR: 42–55);
and for the 60 newly recruited participants, the median
age at study enrollment was 31 (IQR: 28–34).
The number of ARYS participants with at least one
study follow-up visit was 294 (72.6%) and ARYS partici-
pants attended a median of 2 study visits (IQR: 1–3). A
Cheng et al. Substance Abuse Treatment, Prevention, and Policy           (2018) 13:41 Page 3 of 11
total of 646 (85.3%) VIDUS participants had at least one
study follow-up visit and attended a median of 3 study
visits (IQR: 2–3). The first ARYS observation used in
this study was recorded on December 2, 2013 and the
last observation was recorded on May 28, 2015. ARYS
participants contributed a total of 889 observations, of
which 239 (26.9%) included a report of NMPOU. The
first VIDUS observation used in this study was recorded
on December 2, 2013 and the last was recorded on May
29, 2015. VIDUS participants contributed 1877 observa-
tions, of which 411 (21.9%) included a report of
NMPOU. Among 405 ARYS participants included in
this analysis, 39.5% (n = 160) reported engaging in
NMPOU throughout the study period. Among a total of
757 VIDUS participants, 34.6% (n = 262) reported
engaging in NMPOU throughout the study period.
Among ARYS participants in this sample, 135 (33.3%)
were female, and 250 (61.7%) were of Caucasian ethni-
city; VIDUS participants were 33.9% (n = 257) female
and 59.7% (n = 452) Caucasian. Descriptive statistics for
younger (ARYS) and older (VIDUS) participants are dis-
played in Tables 1 and 2. The bivariate and multivariate
analyses for younger participants are displayed in Table 3,
and Table 4 displays the bivariate and multivariate ana-
lyses for older participants. In the multivariate analyses,
engaging in NMPOU was independently and positively as-
sociated with the following factors among both younger
and older participants: injection or non-injection heroin
use (ARYS: Adjusted Odds Ratio [AOR] = 3.12, 95% Con-
fidence Interval [CI]: 2.08–4.68; VIDUS: AOR = 2.79, 95%
CI: 2.08–3.74); drug dealing (ARYS: AOR = 2.22, 95% CI:
1.58–3.13; VIDUS: AOR = 1.87, 95% CI: 1.40–2.49); and
difficulty accessing services (ARYS: AOR = 1.47, 95% CI:
1.04–2.09; VIDUS: AOR = 1.74, 95% CI: 1.32–2.29).
Factors positively and independently associated with
NMPOU among younger (ARYS) participants only in-
cluded: younger age (AOR = 1.12, 95% CI: 1.05–1.19);
crack cocaine use (AOR = 1.56, 95% CI: 1.06–2.30);
and binge drug use (AOR = 1.41, 95% CI: 1.00–1.97).
Among older (VIDUS) participants only, engaging in
NMPOU was independently and positively associated
with injection or non-injection crystal methampheta-
mine use (AOR = 1.97, 95% CI: 1.46–2.66), non-fatal
overdose (AOR = 1.76, 95% CI: 1.20–2.60), and sex
work (AOR = 1.49, 95% CI: 1.00–2.22).
Discussion
Similar proportions of younger and older PWUD re-
ported engaging in NMPOU in this study (40% of ARYS;
35% of VIDUS), and in separate multivariate analyses,
NMPOU was positively associated with heroin use, drug
dealing, and difficulty accessing services among both age
groups. In addition, younger participants who engaged
in NMPOU were more likely to be younger, use crack
Table 1 Characteristics of younger participants stratified by engaging in nonmedical prescription opioid use over the study period,
2013–2015 (n = 405)
Characteristica Total (%)
(n = 405)





Age (M [IQR]) 25 (22–28) 23 (21–26) 26 (23–28) < 0.001
Any cocaine useb, c 123 (30.4) 60 (37.5) 63 (25.7) 0.012
Any crack cocaine useb, c 138 (34.1) 70 (43.8) 68 (27.8) < 0.001
Any crystal meth useb, c 268 (66.2) 121 (75.6) 147 (60.0) 0.001
Any heroin useb, c 193 (47.7) 114 (71.3) 79 (32.2) < 0.001
Any non-fatal overdoseb, c 93 (23.0) 54 (33.8) 39 (15.9) < 0.001
Binge drug useb, c 208 (51.4) 108 (67.5) 100 (40.8) < 0.001
Caucasian ancestry 250 (61.7) 100 (62.5) 150 (61.2) 0.796
Difficulty accessing servicesb, d 151 (37.3) 73 (45.6) 78 (31.8) 0.005
Drug dealingb 131 (32.3) 78 (48.8) 53 (21.6) < 0.001
Female 135 (33.3) 49 (30.6) 86 (35.1) 0.350
Homelessb 202 (49.9) 95 (59.4) 107 (43.7) 0.002
Incarcerationb 57 (14.1) 26 (16.3) 31 (12.7) 0.297
Regular employmentb 191 (47.2) 81 (50.6) 110 (44.9) 0.259
Sex workb 48 (11.9) 26 (16.3) 22 (9.0) 0.027
a. Comparison is yes versus no unless otherwise specified
b. Refers to activities, behaviours, and experiences in the last six months
c. Includes injection and non-injection drug use
d. Includes health and social services
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Table 2 Characteristics of older participants stratified by engaging in nonmedical prescription opioid use over the study period,
2013–2015 (n = 757)
Characteristica Total (%)
(n = 757)





Age (M [IQR]) 48 (40–55) 47 (38–53) 49 (41–56) < 0.001
Any cocaine useb, c 205 (27.1) 98 (37.4) 107 (21.6) < 0.001
Any crack cocaine useb, c 332 (43.9) 135 (51.5) 197 (39.8) 0.002
Any crystal meth useb, c 223 (29.5) 124 (47.3) 99 (20.0) < 0.001
Any heroin useb, c 362 (47.8) 200 (76.3) 162 (32.7) < 0.001
Any non-fatal overdoseb, c 60 (7.9) 43 (16.4) 17 (3.4) < 0.001
Binge drug useb, c 235 (31.0) 118 (45.0) 117 (23.6) < 0.001
Caucasian ancestry 452 (59.7) 164 (62.6) 288 (58.2) 0.239
Difficulty accessing servicesb, d 149 (19.7) 78 (29.8) 71 (14.3) < 0.001
Drug dealingb 171 (22.6) 95 (36.3) 76 (15.4) < 0.001
Female 257 (33.9) 92 (35.1) 165 (33.3) 0.622
Homelessb 149 (19.7) 76 (29.0) 73 (14.7) < 0.001
Incarcerationb 51 (6.7) 28 (10.7) 23 (4.6) 0.002
Regular employmentb 202 (26.7) 59 (22.5) 143 (28.9) 0.059
Sex workb 72 (9.5) 36 (13.7) 36 (7.3) 0.004
a. Comparison is yes versus no unless otherwise specified
b. Refers to activities, behaviours, and experiences in the last six months
c. Includes injection and non-injection drug use
d. Includes health and social services
Table 3 Bivariate and multivariate GEE analyses of factors associated with engaging in nonmedical prescription opioid use among




p - value Odds Ratio
(95% CI)
p - value
Age (per year younger) 1.18 (1.12–1.25) < 0.001 1.12 (1.05–1.19) < 0.001
Any cocaine useb, c 1.68 (1.18–2.39) 0.004 1.31 (0.88–1.95) 0.181
Any crack useb, c 2.16 (1.53–3.05) < 0.001 1.56 (1.06–2.30) 0.023
Any crystal meth useb, c 2.06 (1.42–2.98) < 0.001 –
Any heroin useb, c 4.82 (3.34–6.96) < 0.001 3.12 (2.08–4.68) < 0.001
Any non-fatal overdoseb, c 2.24 (1.61–3.12) < 0.001 1.43 (0.97–2.10) 0.070
Binge drug useb, c 2.36 (1.76–3.15) < 0.001 1.41 (1.00–1.97) 0.049
Caucasian ancestry 1.24 (0.85–1.80) 0.269 –
Difficulty accessing servicesb, d 1.70 (1.27–2.27) < 0.001 1.47 (1.04–2.09) 0.030
Drug dealingb 2.76 (2.03–3.75) < 0.001 2.22 (1.58–3.13) < 0.001
Female 0.91 (0.61–1.36) 0.662 –
Homelessb 1.59 (1.16–2.17) 0.004 –
Incarcerationb 1.32 (0.88–1.99) 0.177 –
Regular employmentb 1.23 (0.92–1.64) 0.168 –
Sex workb 2.11 (1.35–3.29) < 0.001 –
a. Comparison is yes vs. no unless otherwise specified
b. Refers to behaviours, activities, and experiences in the last six months
c. Includes injection and non-injection use
d. Includes health and social services
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cocaine, and engage in binge drug use; older participants
who engaged in NMPOU were more likely to use crystal
methamphetamine, report a recent non-fatal overdose,
and engage in sex work. While younger and older
PWUD in these analyses shared risk factors for engaging
in NMPOU, this study also found important differences
between these two age groups that highlight opportun-
ities to develop targeted efforts that address NMPOU
and unique risks for each age group.
The association between NMPOU and age was not
found to be statistically significant in the analysis of older
participants, which suggests that birth cohorts were not a
meaningful indicator of NMPOU among this sample.
Conversely, the association between NMPOU and youn-
ger age was statistically significant among younger partici-
pants, and this finding may reflect recent trends where
PO use is increasingly prevalent among young age groups
[4, 12, 43]. The increasing use of POs has been attributed
to the availability of POs [4, 17, 44], although the
increased risk for younger birth cohorts using POs may be
more strongly related to the linkages between youth
observing their parents modelling substance use (i.e., PO
use) and then concluding that PO use is safe [4]. Prevent-
ing initiation into injection drug use for youth who engage
in NMPOU is key to reducing the sequelae of harms asso-
ciated with intensifying substance use, and future research
investigating prevention mechanisms is needed.
Younger and older participants who engaged in
NMPOU were significantly more likely to use heroin,
which previous research has found to be used as a replace-
ment for POs when PO availability is low [45]. Although
heroin and POs are both opioids and central nervous sys-
tem depressants, POs are originally obtained from regu-
lated healthcare sources, and heroin is only available
through unregulated illegal drug markets. Acquiring sub-
stances from the street is especially problematic in our
study setting, where the toxic synthetic opioid fentanyl
has adulterated a substantial proportion of the illegal drug
supply [46, 47], and fentanyl-related overdose mortality
has increased alarmingly in various settings across Canada
and the United States [48–51]. To reduce reliance on
illegal heroin, oral medications such as buprenorphine/na-
loxone (Suboxone), methadone, naltrexone, and slow
release morphine have been recommended in recent
opioid treatment guidelines as effective treatments [52],
and injectable opioids such as diacetylmorphine and
hydromorphone are emerging as options for treatment
-refractory opioid dependence [53, 54]. The international
and North American evidence base for heroin assisted
treatment (diacetylmorphine) is strong [53–55], and al-
though less research has been conducted on hydromor-
phone as an injectable opioid treatment, scaling up these
treatments may be an important tool to reduce NMPOU
and exposure to contaminated illegal drugs in Vancouver.
Table 4 Bivariate and multivariate GEE analyses of factors associated with engaging in nonmedical prescription opioid use among




p - value Odds Ratio
(95% CI)
p - value
Age (per year younger) 1.03 (1.10–1.04) < 0.001 0.99 (0.97–1.00) 0.120
Any cocaine useb, c 1.53 (1.18–1.99) 0.001 –
Any crack useb, c 1.42 (1.12–1.81) 0.004 –
Any crystal meth useb, c 2.95 (2.25–3.88) < 0.001 1.97 (1.46–2.66) < 0.001
Any heroin useb, c 3.81 (2.90–4.99) < 0.001 2.79 (2.08–3.74) < 0.001
Any non-fatal overdoseb, c 3.09 (2.12–4.48) < 0.001 1.76 (1.20–2.60) 0.004
Binge drug useb, c 1.71 (1.37–2.14) < 0.001 –
Caucasian ancestry 1.20 (0.90–1.60) 0.225 –
Difficulty accessing servicesb, d 2.11 (1.65–2.69) < 0.001 1.74 (1.32–2.29) < 0.001
Drug dealingb 2.75 (2.10–3.58) < 0.001 1.87 (1.40–2.49) < 0.001
Female 0.97 (0.73–1.31) 0.864 –
Homelessb 2.05 (1.50–2.79) < 0.001 –
Incarcerationb 2.28 (1.47–3.54) < 0.001 1.55 (0.98–2.44) 0.061
Regular employmentb 0.78 (0.60–1.00) 0.055 –
Sex workb 2.05 (1.41–2.98) < 0.001 1.49 (1.00–2.22) 0.049
a. Comparison is yes vs. no unless otherwise specified
b. Refers to behaviours, activities, and experiences in the last six months
c. Includes injection and non-injection use
d. Includes health and social services
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It is important to note that PWUD have long advocated
for access to a wider spectrum of opioid agonist treat-
ments through collaborations with researchers and
coordinated advocacy efforts [56–61]. This study did not
control for intentional or unintentional exposure to
fentanyl or other illicitly manufactured synthetic opioids,
and future research using the ARYS and VIDUS cohorts
would benefit from including exposure to fentanyl in
analyses.
More differences than similarities were found with il-
legal substance use patterns between younger and older
participants. Despite both younger and older PWUD who
engaged in NMPOU being significantly more likely to en-
gage in heroin use, younger participants who engaged in
NMPOU were more likely to also engage in crack cocaine
use and binge drug use, while older participants were
more likely to use crystal methamphetamine in addition
to engaging in NMPOU. Crystal methamphetamine use
may be an important marker of risk for NMPOU among
older individuals in Vancouver, and this finding is con-
cerning given local reports of increasing crystal metham-
phetamine use among adults in Vancouver [62–64].
Historically, crystal methamphetamine use has been more
prevalent among street-involved youth in Vancouver [36],
as 66% of all participants in the younger age group
reported using crystal methamphetamine at baseline; in
addition, crystal methamphetamine has been associated
with initiating injection drug use among this cohort of
youth [65].
The findings from the multivariate model indicate that
NMPOU among younger participants was not associated
with a significantly increased risk for non-fatal overdose,
whereas older participants who engaged in NMPOU were
significantly more likely to report a recent non-fatal over-
dose; however, it should be noted that the confidence inter-
vals for these adjusted odds ratios overlap considerably and
these findings may be attributable to differences in selection
criteria for the ARYS and VIDUS cohorts. This null result
for youth was unexpected given the increased rate of over-
dose associated with PO use [66], and that the comparison
group in this analysis included non-opioid users. These
findings align with previous research findings that older age
is associated with mortality due to unintentional PO
-related overdose [67]. Further research investigating pro-
tective factors associated with a lower risk of overdose
among youth who engage in NMPOU is needed, which
may include specific routes of administration or harm redu-
cing practices related to using a substance with a known
dosage and purity (e.g., prescription opioids versus unregu-
lated heroin of unknown purity and composition). Regard-
less, harm reduction services are critical to ensure that
older PWUD, as well as younger PWUD, who engage in
NMPOU have access to overdose prevention and reversal
services such as supervised drug consumption spaces/
services and the widespread distribution of Naloxone/Nar-
can in the community and among PWUD. The reach of
harm reduction services may also be increased by strategic-
ally mobilizing key peers within PWUDs’ social networks,
which are an untapped resource and could become
important facilitators of harm reduction supplies and
information [68, 69].
Improved access to health and social services is also
especially important in Vancouver, as this study found that
older and younger PWUD who engage in NMPOU were
more likely to report difficulty accessing services. Despite
a saturation of services in the neighbourhoods where
ARYS and VIDUS participants primarily live and congre-
gate (the Downtown South and Downtown Eastside, re-
spectively), there remain important gaps in service design
and access. Previous research among youth in the ARYS
cohort found that local youth-focused shelters and hous-
ing services had strict rules governing entry into- and con-
tinued use of- the service that deterred participants;
conversely, adult or non-youth-specific services were per-
ceived as unsafe or inappropriate for youth [70]. Qualita-
tive research among the VIDUS cohort has found that a
local supervised injection site often has long wait times
that result in people giving up and using drugs elsewhere
[71] and “area restrictions” used by police to prohibit entry
into “drug scenes” impedes access to services and supports
tailored for PWUD and are often specifically located in
areas with high drug use [72]. This finding among younger
PWUD is consistent with previous research from around
the world; youth who use illegal drugs often experience
difficulty accessing services due to stigma and discrimin-
ation from service providers, as well as a lack of
youth-centric health and social services that are preferred
but not widely available [73, 74]. Although the results in-
dicate high rates of illegal polysubstance use in the ARYS
and VIDUS cohorts, participants who only engage in
NMPOU may experience additional difficulties accessing
harm reduction services that are tailored to people who
use illegal drugs, since they and their social networks may
be outside the scope of outreach activities conducted by
these services [75, 76]. More research is required to better
understand specific barriers to accessing health and social
services among youth and adults who engage in NMPOU,
as well as inform effective solutions to fill an important
service gap for these individuals.
Participants in both age groups who engage in NMPOU
were more likely to report recent drug dealing, and older
participants were more likely to report sex work. Drug
dealing has been associated with more intense substance
use among PWUD of Caucasian or white ethnicity [77],
and dealing illegal drugs has been associated with a higher
likelihood of NMPOU among American youth [78]. Our
findings reflect the well-established relationship between
socio-economic marginalization and drug dealing [40, 79],
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and align with consistent research findings that income
from drug dealing [80] and sex work [81] is often used to
sustain ongoing substance use. Despite aligning with pre-
vious research, it is not clear why drug dealing and sex
work remained significantly associated with engaging in
NMPOU after controlling for other illegal drug use; more
research is needed investigating NMPOU and income
generation among individuals not typically recruited in
population-level surveys. Given that difficulty accessing
services was also significantly associated with NMPOU
among younger and older participants, there is a clear
need to improve employment and other services for
PWUD who engage in NMPOU as an intervention to in-
crease socio-economic independence, particularly among
people who engage in sex work. Similar efforts to facilitate
entry into evidence-based addiction treatments for opioid
use such as opioid agonist treatment, heroin assisted treat-
ment, and injectable opioid therapy may reduce the preva-
lence of NMPOU and risky income generating activities.
As there is a lack of evidence to support the effective-
ness of POs for treating chronic pain [82], safer prescrib-
ing to limit the supply and availability of POs is
important for reducing the incidence and prevalence of
NMPOU in the study setting. However, as the supply of
POs becomes more restricted, close surveillance and a
suite of interventions are needed to ensure that those
who engage in NMPOU are not at greater risk for sub-
stituting PO use with contaminated illegal drugs that
have increased overdose risks. Low barrier harm reduc-
tion services to connect with those who engage in
NMPOU and have had difficulty accessing services may
also be an important link to supportive healthcare ser-
vices, social services, and a range of treatment options
for opioid use among younger and older age groups. In
addition, future research investigating the correlates of
incident and recurrent NMPOU over time is needed to
better understand how access to services and changes in
healthcare practices impact NMPOU among high-risk
individuals who use illegal drugs.
There are limitations to this research. First, ARYS and
VIDUS participants may not be representative of all
PWUD in Vancouver and the results therefore not
generalizable to other settings in the city. However, exten-
sive street-based and outreach efforts were undertaken in
order to recruit a representative sample, and the
socio-demographic characteristics of participants in the
ARYS and VIDUS studies are similar to other studies in
Vancouver [83, 84]. Second, this study compares data
from two cohort studies with different inclusion criteria,
which may result in cohort or selection effects. These
cohort effects may affect the results related to homeless-
ness and injection drug use, as these risk factors are also
inclusion criteria for ARYS and VIDUS, respectively.
Given the longitudinal nature of these cohort studies and
extensive efforts to track participants over multiple study
visits, the ARYS and VIDUS studies have observed
changes in behaviours and risk factors over time. For ex-
ample, we have previously reported on transitions out of
homelessness among ARYS participants [85] and injection
cessation among VIDUS participants [86, 87]. In addition,
ARYS and VIDUS have previously been combined in
quantitative and qualitative analyses [72, 88–90]. Third,
social desirability and recall bias may have resulted in er-
roneous reporting of our outcome and independent vari-
ables. Previous research on substance use has found
discrepancies between self-reported substance use and
bioassay test results among American adult male arrestees
[91] and noted concerns that youth may not be truthful
about substance use when speaking with authority figures
who are able to assign punishment [92]. Despite these
findings, self-reported substance use, criminality, and
HIV-related risk-taking among PWUD has also been
deemed sufficiently reliable and valid [93]. Training and
engaging PWUD (“peers”) in survey administration and
data collection methods when conducting substance use
research may be an important mechanism to reduce social
desirability response biases and increase capacity within
communities of PWUD [94, 95]. To reduce socially desir-
able reporting from participants, the ARYS and VIDUS in-
terviewers are trained in building trust and rapport, and
study instruments situate sensitive questions towards the
end of the questionnaire to allow interviewers to build
rapport with participants. Although some socially desir-
able reporting is inevitable, any such reporting from
participants would be expected to under-estimate the
prevalence of sensitive risk factors and therefore our find-
ings likely represent conservative estimates. Less is known
about the accuracy of self-reporting NMPOU among
PWUD; however, efforts to improve the accuracy of
reporting NMPOU among ARYS and VIDUS participants
included using both the generic and brand name of POs,
and showing pictures of a wide variety of POs during
study visits. Fourth, no other information about the cir-
cumstances surrounding non-fatal overdose were included
in this analysis (e.g., what substance was used at the time
of overdose, whether substances were used alone or with
another person, or whether fentanyl contributed to the
overdose); however, the focus of this study was whether
recent NMPOU was an independent marker for overdose
among other risk factors. A more detailed investigation of
the circumstances of overdose among people who engage
in NMPOU is outside the scope of this analysis but is a
promising direction for future research.
Conclusions
The shared risk factors among younger and older partici-
pants who engage in NMPOU underscore the importance
of addressing barriers to accessing health and social
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services, as people who engage in NMPOU appear to be
particularly under-supported and under-served by existing
services for PWUD. Adult PWUD who engage in
NMPOU are also at greater risk of overdose, which high-
lights the need for youth and adult-specific strategies that
focus on reducing high intensity substance use among
youth and providing low barrier overdose prevention and
reversal services for adults. There is an urgent need to
design and implement initiatives to improve healthcare
providers’ skills with managing and treating substance de-
pendence [96], as well as developing pain treatment strat-
egies tailored for PWUD [26]. In addition to developing
services that address youths’ and adults’ unique needs,
policy-makers and healthcare providers are urged to
reduce systematic barriers to a range of addiction treat-
ment options for opioid use that may contribute to reduc-
tions in the prevalence of NMPOU and provide an
additional benefit of preventing other PWUD from initiat-
ing injection drug use [97].
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